West Nile virus in Europe in 2020 - human cases, updated 19 November
Between 13 and 19 November 2020, EU Member States reported one new human case of WNV infection. The case was reported by the Netherlands from the region of Arnhem/ Nijmegen. This region reported a locally acquired human case of WNV infection for the first time through TESSy. One death was reported by Greece. No human cases of WNV infection or deaths were reported from EU-neighbouring countries.
West Nile virus in Europe in 2020 - human cases compared to previous seasons, updated 19 November 2020
Since the start of the 2020 transmission season, and as of 19 November 2020, EU Member States have reported 316 human cases of WNV infection, including 37 deaths, through TESSy: Greece (143, including 23 deaths), Spain (77, including 7 deaths), Italy (66, including 5 deaths), Germany (13), Romania (6, including 1 death), the Netherlands (7), Hungary (3) and Bulgaria (1, including 1 death). The province of Pazardzhik in Bulgaria, the province of Badajoz in Spain, the regions of Utrecht and Arnhem/ Nijmegen in the Netherlands and five regions in Germany (Barnim, Ostprignitz-Ruppin, Saalekreis, Halle (Saale) and Meissen) reported locally acquired human cases of WNV infection for the first time. All other cases reported through TESSy were reported from areas that have been affected during previous transmission seasons.
EU-neighbouring countries reported 17 human cases of WNV infection; all were reported by Israel.
Avian influenza overview – update on 19 November 2020, EU/EEA and the UK
Since 16 October 2020, outbreaks of highly pathogenic avian influenza (HPAI) viruses have been reported in several EU/EEA countries – Belgium, Denmark, France, Germany, Ireland, the Netherlands, and Sweden as well as in the United Kingdom.
Communicable disease threats report, 15-21 November 2020, week 47
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period 15-21 November 2020 and includes updates on COVID-19, Ebola virus disease, dengue, influenza A(H1N2), Legionnaires' disease, seasonal influenza, West Nile fever and TBE.
Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK
This ECDC document is intended to facilitate further discussions between Member States with the aim of reaching agreement on the criteria to be used for the selection of rapid antigen tests, as well as scenarios and settings during which it is appropriate to use rapid antigen tests. This document is also intended to support clinical validations of rapid antigen tests.
Rapid Risk Assessment: Increase in fatal cases of COVID-19 among long-term care facility residents in the EU/EEA and the UK
This risk assessment details the latest epidemiological data in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) with a focus on older age groups and national reports of outbreaks among residents of LTCFs. All EU/EEA countries and the UK have experienced outbreaks among LTCF residents since August 2020.
Contact tracing: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases in the European Union – third update
This document aims to help public health authorities in EU/EEA countries and the UK in their tracing and
management of persons, including healthcare workers, who have had contact with COVID-19 cases.
Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2019
This report is based on data reported to the European Antimicrobial Resistance Surveillance Network (EARS-Net) for the period 2015 to 2019, retrieved from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI) on 10 September 2020.
Antimicrobial consumption - Annual Epidemiological Report for 2019
In 2019, the average total (community and hospital sector combined) consumption of antibacterials for systemic use (Anatomical Therapeutic Chemical (ATC) group J01) in the EU/EEA was 19.4 defined daily doses (DDD) per 1 000 inhabitants per day (country range: 9.5–34.1). During the period 2010–2019, a statistically significant decrease was observed for the EU/EEA overall.